These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6184107)

  • 21. Phenoxybenzamine in prostatic hypertrophy. A double-blind study.
    Ferrie BG; Paterson PJ
    Br J Urol; 1987 Jan; 59(1):63-5. PubMed ID: 2435356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of benign prostatic hyperplasia with phytosterols.
    Carbin BE; Larsson B; Lindahl O
    Br J Urol; 1990 Dec; 66(6):639-41. PubMed ID: 1702340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
    Wien Klin Wochenschr; 1995; 107(15):472-6. PubMed ID: 7545857
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 25. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 27. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy.
    Abrams PH
    Br J Urol; 1977 Feb; 49(1):67-71. PubMed ID: 65196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Male lower urinary tract symptoms and sildenafil.
    Jackson G
    Int J Clin Pract; 2007 Nov; 61(11):1779. PubMed ID: 17935539
    [No Abstract]   [Full Text] [Related]  

  • 30. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.
    Lemack GE
    Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351
    [No Abstract]   [Full Text] [Related]  

  • 31. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy. A controlled study.
    Brooks ME; Sidi AA; Hanani Y; Braf ZF
    Urology; 1983 May; 21(5):474-8. PubMed ID: 6190293
    [No Abstract]   [Full Text] [Related]  

  • 32. Phenoxybenzamine in prostatic obstruction.
    Griffiths DJ; Schröder FH
    Urol Int; 1984; 39(4):241-2. PubMed ID: 6207651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urodynamic and clinical effect of alpha-adrenergic blocker (phenoxybenzamine) in patients with benign prostatic hyperplasia.
    Chen KK; Chang LS; Chen MT; Huang JK; Yin JH; Lin SN; Lin AD
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Feb; 41(2):127-30. PubMed ID: 2458811
    [No Abstract]   [Full Text] [Related]  

  • 34. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia].
    Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514
    [No Abstract]   [Full Text] [Related]  

  • 35. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study.
    Bendix Holme J; Christensen MM; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Elkjaer Husted S
    Scand J Urol Nephrol; 1994 Mar; 28(1):77-82. PubMed ID: 7516576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An endoscopic injection device: a potential advance in the transurethral treatment of benign prostatic obstruction.
    Ditrolio J; Patel P; Watson RA; Irwin RI
    BJU Int; 2003 Jul; 92(1):143-5. PubMed ID: 12823400
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Benign prostatic syndrome. Urinary urgency and micturition frequency reduced with plant preparation].
    MMW Fortschr Med; 2005 Oct; 147(40):52-3. PubMed ID: 16255520
    [No Abstract]   [Full Text] [Related]  

  • 40. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.